Step 1: Linezolid is an oxazolidinone antibiotic used against resistant gram-positive organisms such as MRSA and VRE.
Step 2: Its most important dose-limiting toxicity is myelosuppression, especially thrombocytopenia, which becomes prominent with prolonged use beyond about two weeks. Hence the platelet count (along with the full blood count) must be monitored. Option D is correct.
Step 3: Linezolid is not classically nephrotoxic, so routine renal monitoring is not the key concern. Option A is not the best answer.
Step 4: Hepatotoxicity is not the hallmark adverse effect that drives monitoring. Option B is not the best answer.
Step 5: Auditory (ototoxic) monitoring is needed for aminoglycosides and vancomycin, not for linezolid. Option C is wrong.
Conclusion: The parameter to monitor on linezolid therapy is the platelet count, option D.